arrow_back Back to App

End Drug Price Gouging: Lower Medication Costs for Federal Programs

This bill aims to lower prescription drug prices in the United States. It establishes maximum drug prices based on prices in other developed countries. As a result, citizens covered by federal health programs, as well as uninsured individuals, can expect lower medication costs.
Key points
Setting maximum prescription drug prices based on prices in developed countries like Japan or Germany.
Lower drug prices for individuals covered by Medicare, Medicaid, TRICARE, veterans' and federal employee programs, and for Native Americans.
Drug manufacturers will be required to offer drugs at these lower prices to uninsured individuals and those with private health plans.
Financial penalties for manufacturers who do not comply, with collected funds directed towards drug research and development.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_4215
Sponsor: Rep. Dingell, Debbie [D-MI-6]
Process start date: 2023-06-20
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

End Price Gouging for Medications Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_4215.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-06-20.

What are the main provisions?

Key points include:

  • Setting maximum prescription drug prices based on prices in developed countries like Japan or Germany.
  • Lower drug prices for individuals covered by Medicare, Medicaid, TRICARE, veterans' and federal employee programs, and for Native Americans.
  • Drug manufacturers will be required to offer drugs at these lower prices to uninsured individuals and those with private health plans.
  • Financial penalties for manufacturers who do not comply, with collected funds directed towards drug research and development.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Dingell, Debbie [D-MI-6].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health